CagriSema (Semaglutide + Cagrilintide) — Research Evidence Review (UK POM sensitivity, investigational)

Rationale

CagriSema is Novo Nordisk's investigational fixed-ratio combination of once-weekly semaglutide (a GLP-1 receptor agonist) and once-weekly cagrilintide (a long-acting amylin analogue) delivered from a single injector pen. The rationale is that GLP-1 and amylin activate partially independent satiety pathways: GLP-1 acts largely through vagal afferents and hypothalamic circuits, while amylin's satiety signal is mediated largely via area postrema and hindbrain circuits. Combining a long-acting agonist for each is expected to produce additive effects on food intake and body weight beyond what either agonist alone can achieve, rather than the two pathways simply overlapping and duplicating each other's signal.

The design logic behind the fixed-ratio single-pen delivery is also worth noting: rather than developing cagrilintide as a standalone amylin-receptor agonist and leaving co-administration to the prescriber, Novo Nordisk built the entire clinical development programme around the combination from the earliest phase-1 work. The phase 1b trial (Enebo 2021, Lancet, PMID 33894838) evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of concomitant multiple-dose administration of cagrilintide with semaglutide 2.4 mg, establishing that the two agonists could be co-administered without an unexpected pharmacokinetic interaction before the phase-3 programme was designed.

The programme culminated in the REDEFINE 1 and REDEFINE 2 phase-3 outcome trials (Garvey 2025 and Davies 2025 in NEJM), which reported the weight and glycaemic outcomes at 68 weeks. The REIMAGINE 1-3 phase-3 series (Aroda 2026, Buse 2026, Rosenstock 2026, all Lancet Diabetes & Endocrinology / Lancet) extends the evidence into type-2 diabetes populations across a range of background therapy contexts — diet-and-exercise-only, active comparators, and basal-insulin add-on. Taken together, this is one of the more extensively studied investigational combinations in the incretin/amylin space: seven separate publications across phase 1b through phase 3, spanning obesity, obesity-with-T2D, and multiple T2D subpopulations.

Evidence tier

Grade B — human RCT evidence, not yet licensed. Phase 3 RCT outcomes at 68 weeks in obesity (REDEFINE 1) and obesity + T2D (REDEFINE 2), with additional phase 3 data in T2D across three further trials (REIMAGINE 1-3). This evidence tier reflects a substantial and consistent randomised-controlled-trial base — not a single pivotal trial, but a coordinated multi-trial programme across overlapping and distinct populations — while stopping short of "Grade A / licensed" because no regulatory body has yet reviewed and approved the combination. See our evidence-level classifier for how these grades are assigned.

Not licensed by the MHRA, FDA, or EMA as of 2026-07. That regulatory gap is the single most important fact for a UK reader to hold onto: strong trial evidence and formal licensing are not the same thing, and CagriSema currently has the former without the latter. Long-term (multi-year) safety, cardiovascular-outcome data, and durability-after-cessation data are not yet reported in any of the seven publications in this page's reference list, which is also typical for a combination still working through its phase-3 programme rather than an established, licensed medicine with years of post-marketing surveillance behind it.

Study methodology summary

REDEFINE 1 and REDEFINE 2 titrated participants from a starting dose of 0.25 mg of each component to a maintenance dose of 2.4 mg + 2.4 mg over roughly 16 weeks, then continued at maintenance dose to week 68. The regimen was administered subcutaneously once weekly under formal clinical-trial supervision, with active comparators (placebo and, in REDEFINE 1, semaglutide 2.4 mg monotherapy). REDEFINE 1 enrolled adults with overweight or obesity without type-2 diabetes; REDEFINE 2 enrolled adults with overweight or obesity and type-2 diabetes, allowing the glycaemic endpoints to be assessed in a population where they are clinically meaningful.

REIMAGINE 1-3 use similar titration and maintenance patterns in type-2 diabetes populations, but differ in background therapy and comparator design, which is why the three trials are reported separately rather than pooled. REIMAGINE 1 (Aroda 2026, Lancet Diabetes & Endocrinology, PMID 42251860) evaluated CagriSema against placebo in adults with T2D inadequately controlled on diet and exercise alone — the "least confounded" T2D population, without background glucose-lowering medication to account for. REIMAGINE 2 (Buse 2026, Lancet Diabetes & Endocrinology, PMID 42251859) compared CagriSema against its individual components — semaglutide alone and cagrilintide alone — in people with T2D, which is the closest this programme comes to isolating each component's independent contribution within a T2D population, rather than only comparing the combination to placebo. REIMAGINE 3 (Rosenstock 2026, Lancet, PMID 42251856) added CagriSema on top of existing basal insulin therapy, a background-medication context relevant to a more advanced T2D population already on injectable glucose-lowering treatment.

Across all five phase-3 trials, the methodology is consistent: randomised, double-blind, placebo-controlled (with active comparators where noted), multicentre, with weight and/or HbA1c as co-primary or key secondary endpoints depending on the trial's enrolled population.

This consistency of methodology across five separately published trials is itself a notable feature of the evidence base. Rather than a single large trial covering a heterogeneous population, Novo Nordisk's programme deliberately segmented the populations — obesity without T2D, obesity with T2D, T2D on diet/exercise only, T2D against active comparators, and T2D on background insulin — so that each trial's result can be read against a relatively well-defined comparator group. The trade-off is that no single trial in the reference list answers the question "what does CagriSema do across the full range of metabolic disease severity"; each answers a narrower question about a specific population, and a reader has to look across the REDEFINE and REIMAGINE trials together to build the fuller picture.

The Verma 2026 (Hypertension, PMID 41328546) publication is a sub-analysis of REDEFINE 1 rather than an independent trial — it reanalyses blood-pressure data collected within the REDEFINE 1 trial population specifically, rather than enrolling a new cohort. That distinction matters for evidence-weighting: a sub-analysis of an existing trial's data carries a different evidentiary status than a dedicated, purpose-designed outcome trial, even when both are peer-reviewed and published in reputable journals.

What the evidence does and does not support

Supported (on the studied populations, over the reported trial durations):

• Greater mean weight reduction than placebo in REDEFINE 1 and REDEFINE 2.
• Greater mean weight reduction than semaglutide 2.4 mg alone in REDEFINE 1's head-to-head comparator arm.
• Greater HbA1c reduction than semaglutide 2.4 mg alone in REDEFINE 2 in participants with T2D.
• Modest but statistically-significant blood-pressure reductions (REDEFINE 1 sub-analysis, Verma 2026, PMID 41328546).
• Glycaemic benefit in T2D populations inadequately controlled on diet and exercise alone, without background medication confounding (REIMAGINE 1, Aroda 2026).
• A comparison of CagriSema against its individual components within a T2D population (REIMAGINE 2, Buse 2026), which is the closest the published record comes to separating the combination's added value from either agonist alone in that population.
• Additional glycaemic and/or weight benefit when added on top of existing basal insulin therapy in T2D (REIMAGINE 3, Rosenstock 2026).

Not yet supported (no published evidence in this page's reference list):

• Cardiovascular outcome benefit (a SELECT-equivalent dedicated cardiovascular outcomes trial has not been reported for CagriSema).
• Long-term (>2 year) safety.
• Durability of weight loss or glycaemic control after discontinuation.
• Effects on muscle mass and body composition beyond the DEXA-type endpoints reported in the primary REDEFINE papers.
• Real-world effectiveness outside the trial populations — all evidence to date comes from formally randomised, closely monitored trial cohorts, which are not the same as unselected real-world prescribing populations.
• A regulatory decision (approval or rejection) from the MHRA, FDA, or EMA.

Practical implications for research literacy

For a UK-based reader trying to place CagriSema correctly, the practical implication is straightforward: this is a well-studied investigational combination, not an available or imminent treatment option. The volume of phase-3 evidence — five separate randomised trials spanning obesity and multiple T2D subpopulations — is unusually deep for a combination that has not yet been reviewed by a regulator. That depth is worth distinguishing from licensing status: a combination can have a large, consistent, multi-trial evidence base and still be years away from (or never reach) a marketing authorisation, and the two facts should be evaluated separately rather than treating "lots of trials" as equivalent to "approved."

It is also worth being precise about what "greater than semaglutide alone" means across these trials. REDEFINE 1's head-to-head comparator arm and REIMAGINE 2's component-comparison design are the two places in this evidence base where CagriSema is compared directly against semaglutide (and, in REIMAGINE 2, against cagrilintide) rather than only against placebo. Most of the individual outcome figures — the specific percentage weight reductions and HbA1c changes — are reported in the primary NEJM and Lancet publications rather than restated here; readers who need those exact figures should consult the primary sources directly rather than relying on a secondary summary.

Finally, because no monotherapy phase-3 trial for cagrilintide exists outside its combination with semaglutide, any reading of "cagrilintide's effect" in isolation should be treated cautiously — the closest the literature comes to isolating it is the component-comparison design in REIMAGINE 2, and even that is a single trial in a T2D population rather than a comprehensive standalone cagrilintide evidence base.

Readers should also be careful about extrapolating trial-population results to a general population. Every figure in the "Supported" list above comes from formally randomised, closely monitored, protocol-defined trial cohorts — participants who met specific inclusion and exclusion criteria, were dosed under direct clinical-trial supervision, and were followed with structured visit schedules. None of that guarantees the same magnitude of effect, or the same safety profile, in an unselected population outside a trial setting, which is one of the standard reasons regulators require post-marketing surveillance even after a positive phase-3 programme and formal licensing — a stage CagriSema has not yet reached.

Related evidence review

Readers wanting the mechanistic and regulatory context that sits either side of this evidence summary should see the Tirzepatide vs Cagrilintide comparison, which contrasts CagriSema's amylin+GLP-1 approach against tirzepatide's licensed dual GIP/GLP-1 mechanism, and the CagriSema mechanism explainer, which covers the amylin- and GLP-1-receptor biology underpinning the rationale described above in more depth. The semaglutide monograph is the relevant reference for the licensed GLP-1 component of this combination, which — unlike cagrilintide — has an existing UK marketing authorisation and prescribing history as Wegovy and Ozempic.

UK regulatory context

Neither cagrilintide nor CagriSema is a licensed medicine in the UK as of 2026-07. Under the MHRA's rules for unlicensed medicines and the ASA's advertising codes, promotional claims about CagriSema for weight loss are prohibited. See our page on prescription-only medicine advertising and the weight-loss medicine advertising caution for the framework.

Semaglutide monotherapy — the GLP-1 arm of the combination — IS licensed in the UK as Wegovy (weight management) and Ozempic (T2D). See the semaglutide monograph for its UK regulatory status.

Related pages

• Cagrilintide monograph — the amylin arm
• Semaglutide monograph — the GLP-1 arm
• Tirzepatide vs Cagrilintide comparison — incretin vs amylin approach
• CagriSema mechanism explainer
• GLP-1 & Incretin Research Hub